



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 22 August 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (“SEBI LISTING REGULATIONS”) – RECEIPT OF SHOW CAUSE NOTICE

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para B(8) of Part A of the Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”) and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended (collectively, “Applicable Laws”), we hereby inform that the Company has received a show cause cum demand notice from Directorate General of GST Intelligence, Mumbai, alleging non-payment of IGST on reverse charge mechanism for import of services. The above-mentioned notice refers to the Company’s acquisition of trademark rights along with the title of “Zomelis” and its associated brands, registered in India, from Novartis AG Switzerland by assignment deed dated November 27, 2019.

The details as required under the Applicable Laws are provided in the **Annexure**. The Company is evaluating this matter and based on the advice of its tax consultants, it will submit its reply within the prescribed time period.

The Company maintains a scrupulous record of financial dealings, and contribute towards nation-building as a responsible business. Our compliances are in line with the letter, spirit and intent of the law, and aligned with prevailing industry practices.

Kindly take this intimation on your record.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Encl.: Annexure

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Annexure

Pendency of any litigation(s) or dispute(s) or the outcome thereof which may have an impact on the listed entity:

S. No.	Particulars	Details
a)	Brief details of litigation, viz.: Name(s) of the opposing party, Court/tribunal/agency where litigation is filed, brief details of dispute/litigation.	<p>The Company has received a show cause cum demand notice from Directorate General of GST Intelligence, Mumbai, alleging non-payment of IGST on reverse charge mechanism for import of services, under Section 74(1) of the CGST Act, 2017 read with relevant provisions of the State GST Act, 2017 & IGST Act, 2017 and applicable circulars. The above-mentioned notice refers to the Company's acquisition of trademark rights along with the title of "Zomelis" and its associated brands, registered in India, from Novartis AG Switzerland by assignment deed dated November 27, 2019.</p> <p>The Company is evaluating this notice and based on the advice of its tax consultants, it will submit its reply within the prescribed time period.</p>
b)	Expected financial implications, if any (compensation, penalty, etc.).	<p><u>Expected financial implication:</u> IGST demand: Rs. 16,84,67,040/- Applicable Interest: 18% p.a. from November 27, 2019 Penalty: Not specified under the notice</p> <p>The Company is of the view that it has complied with the said provisions of the GST laws and has a good case on merits. In case the Company succeeds in these proceedings before the concerned Authorities, the demand will not be upheld.</p>
c)	Quantum of claims, if any	None

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867